Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus

NCT07201558 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07201558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07201558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
December 2, 2025
Completion date
June 27, 2028
Enrollment
48 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis, systemic lupus erythematosus